Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease.

Alzheimers Dement (N Y) · 2021 · PMC7988877 · PMID 33778150

Europe PMC DOI

hedged sentence

0.0632

closest p · 1.3× alpha

0.0632

boldest claim

The sentences

nearly statistically significantP = .0632so close (0.05 < p ≤ 0.1)

37 The memory domain subscale of ADAS‐Cog13 30 at EOT (when the MMSE showed a statistically significant improvement) showed a nearly statistically significant trending improvement in the sargramostim group compared to placebo ( P = .0632), suggesting that the sargramostim treatment effect is primarily on the memory domain (Figure 3B ; Table S8 in supporting information).

also in 323 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.